JP2013522311A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522311A5
JP2013522311A5 JP2013500162A JP2013500162A JP2013522311A5 JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5 JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5
Authority
JP
Japan
Prior art keywords
phe
lys
arg
aromatic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028543 external-priority patent/WO2011116007A1/en
Publication of JP2013522311A publication Critical patent/JP2013522311A/ja
Publication of JP2013522311A5 publication Critical patent/JP2013522311A5/ja
Pending legal-status Critical Current

Links

JP2013500162A 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法 Pending JP2013522311A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31394510P 2010-03-15 2010-03-15
US61/313,945 2010-03-15
US37681310P 2010-08-25 2010-08-25
US61/376,813 2010-08-25
PCT/US2011/028543 WO2011116007A1 (en) 2010-03-15 2011-03-15 Combination therapies using cyclosporine and aromatic cationic peptides

Publications (2)

Publication Number Publication Date
JP2013522311A JP2013522311A (ja) 2013-06-13
JP2013522311A5 true JP2013522311A5 (https=) 2014-05-01

Family

ID=44649559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500162A Pending JP2013522311A (ja) 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法

Country Status (4)

Country Link
US (4) US8697657B2 (https=)
EP (6) EP3375449A1 (https=)
JP (1) JP2013522311A (https=)
WO (1) WO2011116007A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3375449A1 (en) 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
AU2012315586B2 (en) * 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
JP2014196281A (ja) * 2012-08-01 2014-10-16 健輔 江頭 医薬組成物
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
CA2912386A1 (en) * 2013-05-14 2014-11-20 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricular remodeling
US20140363391A1 (en) * 2013-06-06 2014-12-11 Demetris Yannopoulos System and method for administering poloxamers and anesthetics while performing cpr and minimizing reperfusion injury
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
WO2015023680A1 (en) * 2013-08-12 2015-02-19 Stealth Peptides International, Inc. Combination therapy for the treatment of ischemia-reperfusion injury
JP6626446B2 (ja) 2013-12-27 2019-12-25 ステルス バイオセラピューティックス コープ 薬学的に適切な芳香族カチオン性ペプチド
HK1231493A1 (zh) * 2014-03-03 2017-12-22 Stealth Biotherapeutics Corp 药学上相关的芳香族阳离子肽
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
EP3149035A4 (en) * 2014-05-28 2018-05-16 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015183995A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2016029027A2 (en) 2014-08-21 2016-02-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
US10683534B2 (en) * 2015-01-27 2020-06-16 BioSpyder Technologies, Inc. Ligation assays in liquid phase
CA2976632A1 (en) * 2015-02-13 2016-08-18 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
US10633415B2 (en) 2015-03-06 2020-04-28 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
CN110914287A (zh) 2017-04-05 2020-03-24 隐形生物治疗公司 Boc-d-arg-dmt-lys-(boc)-phe-nh2的结晶盐形式
WO2018223032A1 (en) * 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
US12404300B2 (en) 2018-12-18 2025-09-02 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
EP3898653A4 (en) 2018-12-18 2022-08-24 Stealth BioTherapeutics Inc. ANALOGS TARGETING MITOCHONDRIAL DISEASES
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5786332A (en) 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
CA2381425A1 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20080194470A1 (en) * 2004-04-08 2008-08-14 Novartis Ag Nim811 In Cerebral Ischemia and Brain and Spinal Cord Injury
EP2023948A1 (en) * 2006-05-04 2009-02-18 Michel Ovize Use of cyclosporin a or melle4-cyclosporin for the treatment of acute myocardial infarction
EP2114427B1 (en) * 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
PL2470191T3 (pl) * 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP3266462A1 (en) 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
AU2011207432A1 (en) 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Similar Documents

Publication Publication Date Title
JP2013522311A5 (https=)
CA2915005C (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ES2425083T3 (es) Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
ES2398012T5 (es) Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
ES2484315T3 (es) Tratamiento de la pérdida del sentido del tacto con derivados de saxitoxina
JP2009102342A5 (https=)
JP2011500851A5 (https=)
JP2011241213A5 (https=)
JP2013515739A5 (https=)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2015522630A5 (https=)
TW201601743A (zh) 外周ｋａｐｐａ鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途
JP2013518124A5 (https=)
JP2008517991A5 (https=)
JP2020510043A5 (https=)
JP2009500045A5 (https=)
WO2009151714A3 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
TWI496579B (zh) 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途
ES2671024T3 (es) Composición farmacéutica para administración transnasal
WO2021216678A1 (en) Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same